Company R&D and production center

R&D and Production Center


The company's current IVD technology platforms for product development include high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis platform, immunoassay platform, and nucleic acid detection platform. The Company will further establish PocT and microfluidic technology platforms in the future for the development of home-based diagnostic products.

The Company has advanced self-research capability for raw materials, a large molecule protein expression technology platform, polyclonal antibody and monoclonal antibody preparation technology platforms, achieving a high degree of autonomy of self-research products with strong competitiveness.

The latex-enhanced turbidimetric immunoassay (LETIA) developed by the Company is characterized by high sensitivity, universal application in large/small molecule detection, low matrix interference. The TDM series test products developed using the platform have passed the NMPA, CE, IS013485 and FDA certification, and have and have been approved and applied by many tertiary hospitals in China.



R & D

Medical Device R&D(Device products)

Genext 's current device research and development is mainly focused on the equipment for kidney and liver procurement, perfusion, preservation, repair, and transportation.

Genext has well developed R&D and quality management system, have strong expertise in the perfusion control system, low temperature management and sterile consumables design and manufacturing,

On the base of current HMP device, Genext is keeping innovation with integration the latest technology and clinical requirement.

At the same time, Genext continues to expand and develop new product lines in combination with domestic and international clinical needs. Form a product family and series with liver and kidney perfusion equipment as the core, and deeply cultivate the dedicated track.

R & D